ES2180546T3 - Composicion basica administrable percutaneamente y composicion de farmaco preparada a partir de ella. - Google Patents

Composicion basica administrable percutaneamente y composicion de farmaco preparada a partir de ella.

Info

Publication number
ES2180546T3
ES2180546T3 ES93916216T ES93916216T ES2180546T3 ES 2180546 T3 ES2180546 T3 ES 2180546T3 ES 93916216 T ES93916216 T ES 93916216T ES 93916216 T ES93916216 T ES 93916216T ES 2180546 T3 ES2180546 T3 ES 2180546T3
Authority
ES
Spain
Prior art keywords
composition
weight
drug
percutaneously
administrable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93916216T
Other languages
English (en)
Inventor
Naruhito Higo
Yukio Kojima
Ken-Ichi Komori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hisamitsu Pharmaceutical Co Inc
Original Assignee
Hisamitsu Pharmaceutical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hisamitsu Pharmaceutical Co Inc filed Critical Hisamitsu Pharmaceutical Co Inc
Application granted granted Critical
Publication of ES2180546T3 publication Critical patent/ES2180546T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Seasonings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UNA COMPOSICION BASE ADMINISTRABLE PERCUTANEAMENTE QUE FACILITA LA ABSORCION PERCUTANEA DE DROGAS Y ES REMARCABLEMENTE REDUCIDA LA IRRITACION CONTRA LA PIEL QUE PRODUCE. LA COMPOSICION COMPRENDE 10-60 % DE PESO DE ALCOHOL INFERIOR, 10-50 % DE PESO DE HUMIDIFICADOR, 10-70 % DE PESO DE AGUA, 0,1-15% DE PESO DE PREIRRITANTE Y 0,1-15 % DE PESO DE PROMOTOR DE ABSORCION. UNA COMPOSICION DE DROGA SE PREPARA AÑADIENDO A LA COMPOSICION ANTERIOR VARIOS INGREDIENTES ACTIVOS TALES COMO ANTITUSIVOS, EXPECTORANTES, RELAJANTES DE MUSCULO DE ESQUELETO, DROGA ANTI-VERTIGO, NARCOTICO, DROGA PARA EL SISTEMA CIRCULATORIO, ETCETERA.
ES93916216T 1992-07-23 1993-07-23 Composicion basica administrable percutaneamente y composicion de farmaco preparada a partir de ella. Expired - Lifetime ES2180546T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21836992 1992-07-23
JP22922692 1992-08-04

Publications (1)

Publication Number Publication Date
ES2180546T3 true ES2180546T3 (es) 2003-02-16

Family

ID=26522528

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93916216T Expired - Lifetime ES2180546T3 (es) 1992-07-23 1993-07-23 Composicion basica administrable percutaneamente y composicion de farmaco preparada a partir de ella.

Country Status (9)

Country Link
US (1) US5932227A (es)
EP (1) EP0651993B1 (es)
CN (1) CN1076972C (es)
AT (1) ATE225646T1 (es)
AU (1) AU4585493A (es)
CA (1) CA2140901A1 (es)
DE (1) DE69332378T2 (es)
ES (1) ES2180546T3 (es)
WO (1) WO1994002119A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2753800B2 (ja) * 1994-04-14 1998-05-20 日東電工株式会社 経皮吸収型製剤
US5733900A (en) * 1994-04-21 1998-03-31 Hisamitsu Pharmaceutical Co., Inc. Percutaneous administration base composition and percutaneous administration medicinal composition comprising said base composition and medicine
EP0747092B1 (en) * 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoresis
IT1309588B1 (it) * 1999-03-05 2002-01-24 Altergon Sa Cerotto con spessore sottile contenente betametasone ed acidoialuronico per il trattamento di psoriasi, dermatite, dermatosi.
DE19950066A1 (de) * 1999-10-16 2001-04-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einem Gehalt an Tulobuterol-hydrochlorid zur Verabreichung des Bronchodilatators Tulobuterol über die Haut
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
JP4387639B2 (ja) * 2002-07-16 2009-12-16 久光製薬株式会社 経皮吸収製剤
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0417675D0 (en) * 2004-08-09 2004-09-08 Futura Medical Dev Ltd Composition for promoting vascular smooth muscle relaxation
WO2006085521A1 (ja) * 2005-02-10 2006-08-17 Nihon University オピオイドレセプター拮抗剤を含有する経皮吸収用医薬組成物およびその製造方法、並びに前記拮抗剤の経皮吸収促進方法
US7655700B2 (en) 2005-08-25 2010-02-02 Michigan State University Transgenic mouse model and methods for treatment of neuro muscular disease by interfering with androgen-androgen receptor interaction in skeletal muscles
SI2450041T1 (sl) 2005-10-12 2019-02-28 Unimed Pharmaceuticals, Llc Izboljšan testosteronski gel za uporabo pri zdravljenju hipogonadizma
GB0602224D0 (en) * 2006-02-03 2006-03-15 Futura Medical Dev Ltd Composition for promoting vascular smooth muscle relaxation
WO2017057743A1 (ja) * 2015-09-30 2017-04-06 富士フイルム株式会社 経皮吸収用組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
US4552872A (en) * 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
DE3406497A1 (de) * 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung
US4855294A (en) * 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
JPH0725669B2 (ja) * 1988-12-23 1995-03-22 日東電工株式会社 経皮投与用医薬製剤
DE4002281A1 (de) * 1990-01-26 1991-08-01 Lohmann Therapie Syst Lts Transdermales therapeutisches system mit dem wirkstoff tulobuterol
PT99338A (pt) * 1990-10-29 1992-10-30 Alza Corp Processo para a preparacao de composicoes de farmacos anticoncepcionais administradas transdermicamente contendo uma mistura dum estrogeno e gestodeno e dispositivos para a sua administracao transdermica

Also Published As

Publication number Publication date
CN1089507A (zh) 1994-07-20
WO1994002119A1 (fr) 1994-02-03
CN1076972C (zh) 2002-01-02
AU4585493A (en) 1994-02-14
EP0651993A1 (en) 1995-05-10
US5932227A (en) 1999-08-03
DE69332378T2 (de) 2003-07-10
EP0651993B1 (en) 2002-10-09
DE69332378D1 (de) 2002-11-14
EP0651993A4 (en) 1997-02-26
CA2140901A1 (en) 1994-02-05
ATE225646T1 (de) 2002-10-15

Similar Documents

Publication Publication Date Title
ES2180546T3 (es) Composicion basica administrable percutaneamente y composicion de farmaco preparada a partir de ella.
EP2134319B1 (en) Compositions comprising a physiological coolant
HUP9802384A2 (hu) Biológiailag hatásos 1,3-propán-diol-származékok és ezek alkalmazása
JPH0640904A (ja) 医薬組成物
US20140287058A1 (en) Composition for maintaining bone health and for treating osteoarthritis and osteoarthrosis of the joints
DE69518008D1 (de) Steigerung der kreatin und glykogen konzentration im muskel
CN105476902A (zh) 一种婴幼儿皮肤防皲裂乳霜
JPH1077222A (ja) バクテリア、菌及びウイルスに対して活性で部分グリセリド及びジアルキル−置換酢酸に基づく活性化合物組み合わせ
SE8001599L (sv) Transdermalt medicineringssystem for isosorbiddinitrat
DK403187A (da) Praeparat til transdermal indgift
Setnikar et al. Pharmacological properties of piperidinoethyl-3-methylflavone-8-carboxylate hydrochloride, a smooth-muscle relaxant
CN101152123B (zh) 一种妇女、儿童用沐浴盐膏
ES2087623T3 (es) Derivados de bencimidazol como agente antimicrobiano contra campylobacter pylon.
EP0535237A4 (en) Composition for relieving skin irritation and external preparation for percutaneous adminstration containing the same
FR2712809B1 (fr) Nouvelle composition pharmaceutique destinée à la préparation d'une poudre stable contenant, à titre d'ingrédient actif, une association d'acide acétylsalicylique et de métoclopramide.
ES2052000T3 (es) Procedimiento para preparar composiciones farmaceuticas que contienen pentamidina.
RU96105945A (ru) Терапевтическая готовая лекарственная форма
KR900007434A (ko) 시스타틴을 유효 성분으로하는 치료제
CN108904409A (zh) 一种婴儿护肤专用平安膏
US4983625A (en) Psoralene-based bath compositions for treatment of skin disorders
JPH08301780A (ja) 脂肪分解促進剤
Horlick The effect of artificial modification of food on the serum cholesterol level
Bernardis et al. Blood pressure in female and male rats following ventromedial hypothalamic lesions placed at four different ages.
CN115252479A (zh) 一种止痒消炎驱蚊露配方
TW328049B (en) Penciclover/propylene glycol composition